Peptide receptor radionuclide therapy for recurrent neuroendocrine tumors after liver transplantation

doi:10.3748/wjg.121126

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 45

This Article

(0)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Dec 7, 2026; 32(45): 121126
Published online Dec 7, 2026. doi: 10.3748/wjg.121126

Table 2 Individual patient characteristics and treatment outcomes in the peptide receptor radionuclide therapy group (n = 7)

Case	Tumor recurrence time after LT (month)	Everolimus level (ng/mL)	Time from LT to PRRT (month)	PRRT with ¹⁷⁷Lu-DOTATATE cycles	PRRT with ¹⁷⁷Lu-DOTATATE cumulative dose (mCi)	Myelosuppression (grade)	Proteinuria (grade)
1	7	6.8	42	2	327	III	II
2	3	7.5	6	4	709	II	None
3	3	5.2	14	3	502	II	None
4	9	7.2	9	1	175	III	I
5	6	4.5	22	2	327	II	None
6	3	5.8	12	3	502	II	I
7	3	3.8	12	2	327	I	I

Adverse events were graded according to Common Terminology Criteria for Adverse Events version 5.0. “None” indicates no proteinuria detected. GBq: Gigabecquerel (1 mCi = 0.037 GBq); mCi: Millicurie; LT: Liver transplantation; PRRT: Peptide receptor radionuclide therapy; ¹⁷⁷Lu-DOTATATE: Lutetium Lu 177 dotatate.

Full Size Table

Citation: Zheng QM, Chen CY, Zhang L, Sun JS, Wang HH, Xie Y, Guo QJ, Jiang WT. Peptide receptor radionuclide therapy for recurrent neuroendocrine tumors after liver transplantation. World J Gastroenterol 2026; 32(45): 121126
URL: https://www.wjgnet.com/1007-9327/full/v32/i45/121126.htm
DOI: https://dx.doi.org/10.3748/wjg.121126

Zheng QM, Chen CY, Zhang L, Sun JS, Wang HH, Xie Y, Guo QJ, Jiang WT. Peptide receptor radionuclide therapy for recurrent neuroendocrine tumors after liver transplantation. World J Gastroenterol 2026; 32(45): 121126 [DOI: 10.3748/wjg.121126]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.